- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00982150
Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) (ALSTAR OL)
August 16, 2013 updated by: Teva Branded Pharmaceutical Products R&D, Inc.
A Multinational, Multicenter, Open Label Phase to Assess Tolerability and Safety of Talampanel 50mg Tid in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This will be an open label treatment extension phase in patients with ALS who have previously participated in the double blind, placebo-controlled ALS-TAL-201 study.
This study will make talampanel treatment available to all subjects who completed the double blind placebo-controlled phase of ALS-TAL-201 study and where the investigator and patient consider it to be in the patient's interest to receive talampanel 50mg three times daily (tid).
It will also enable the exploration of long-term safety and tolerability of talampanel 50mg tid.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
446
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have completed 52 weeks of treatment of the double blind placebo-controlled phase of ALS-TAL-201.
- Women must be postmenopausal, surgically sterile, or using adequate birth control methods.
- Patients must be willing and able to give written informed consent prior to performing any open-label study procedures.
Exclusion Criteria:
- Patients with ECG signs of Brugada syndrome and/ or complete or incomplete Right Bundle Branch Block
Patients using any of the following:
- Chronic use of lithium carbonate
- Chronic use of mecasermin (rhIGF-1)
- Chronic use of minocycline
- Chronic use of more than 600mg/day coenzyme Q10
- Chronic use of any marketed drug, if its use was not clearly indicated for any underlying medical condition other than ALS (symptomatic drugs for ALS and supplements allowed)
- Patients participating in any other investigational drug study and use of any other investigational drug
- Patients taking drugs that may interact with Talampanel
- Females who are pregnant or nursing.
- Females of child-bearing potential who do not practice medically acceptable methods of contraception.
- Any condition of the patient which the investigator feels may interfere with participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Talampanel
Talampanel 50mg tid
|
50mg capsules tid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ALSFRS-R
Time Frame: every 4 weeks
|
every 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Vital Signs, ECG, Adverse Event Reports
Time Frame: every 26 weeks
|
every 26 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
September 22, 2009
First Submitted That Met QC Criteria
September 22, 2009
First Posted (Estimate)
September 23, 2009
Study Record Updates
Last Update Posted (Estimate)
August 26, 2013
Last Update Submitted That Met QC Criteria
August 16, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALS-TAL-201-OL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on Talampanel
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.CovanceTerminated
-
National Institute of Neurological Disorders and...Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.National Cancer Institute (NCI)TerminatedGlioblastoma Multiforme | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Anaplastic Mixed Oligoastrocytoma
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedParkinson Disease | Movement Disorders | Dyskinesias
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedGlioblastoma Multiforme
-
National Institute of Neurological Disorders and...Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedALSUnited States, Netherlands, Canada, Italy, Spain, Belgium, France, Germany, Hungary, Israel
-
Teva Branded Pharmaceutical Products R&D, Inc.Cetero Research, San AntonioCompleted